165 related articles for article (PubMed ID: 9372040)
1. Strategies for viral inactivation.
Horowitz B; Ben-Hur E
Curr Opin Hematol; 1995 Nov; 2(6):484-92. PubMed ID: 9372040
[TBL] [Abstract][Full Text] [Related]
2. Transfusion-transmitted infection in hemophilia in developing countries.
Yee TT; Lee CA
Semin Thromb Hemost; 2005 Nov; 31(5):527-37. PubMed ID: 16276461
[TBL] [Abstract][Full Text] [Related]
3. Specific inactivation of viruses which can potentially contaminate blood products.
Horowitz B
Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
[TBL] [Abstract][Full Text] [Related]
4. Safety of plasma derivatives.
Ingerslev J
Haemostasis; 1994; 24(5):311-23. PubMed ID: 7843643
[TBL] [Abstract][Full Text] [Related]
5. [Safety of transfusion therapy with special emphasis on inactivated viruses in products made from human blood].
Patko MS; Balija M; Grgicević D
Lijec Vjesn; 1995; 117(9-10):216-21. PubMed ID: 8643012
[TBL] [Abstract][Full Text] [Related]
6. Safety procedures of coagulation factors.
Jorquera JI
Haemophilia; 2007 Dec; 13 Suppl 5(Suppl 5):41-6. PubMed ID: 18078396
[TBL] [Abstract][Full Text] [Related]
7. Virus inactivation procedures: an overview.
Tedder R
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S13-4. PubMed ID: 7495960
[TBL] [Abstract][Full Text] [Related]
8. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
9. Beyond HIV, HBV and HCV--how to deal with other viruses?
Minor PD
Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138
[TBL] [Abstract][Full Text] [Related]
10. Evolving perspectives in product safety for haemophilia.
Farrugia A
Haemophilia; 2002 May; 8(3):236-43. PubMed ID: 12010417
[TBL] [Abstract][Full Text] [Related]
11. Viral safety of clotting factor concentrates.
Fricke WA; Lamb MA
Semin Thromb Hemost; 1993; 19(1):54-61. PubMed ID: 8456324
[TBL] [Abstract][Full Text] [Related]
12. Viral safety of solvent/detergent-treated blood products.
Horowitz B; Prince AM; Hamman J; Watklevicz C
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S21-8; discussion S29-S30. PubMed ID: 7749045
[TBL] [Abstract][Full Text] [Related]
13. Viral safety of haemophilia treatment products.
Teitel JM
Ann Med; 2000 Oct; 32(7):485-92. PubMed ID: 11087169
[TBL] [Abstract][Full Text] [Related]
14. Transfusion-transmissible infections.
Vrielink H; Reesink HW
Curr Opin Hematol; 1998 Nov; 5(6):396-405. PubMed ID: 9814646
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of viruses found with plasma proteins.
Horowitz B
Biotechnology; 1991; 19():417-30. PubMed ID: 1786476
[TBL] [Abstract][Full Text] [Related]
16. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates.
Burnouf T
Biologicals; 1992 Jun; 20(2):91-100. PubMed ID: 1389114
[TBL] [Abstract][Full Text] [Related]
17. Prevention of infections transmissible by blood derivatives.
Barbara JA
Transfus Sci; 1998 Mar; 19(1):3-7. PubMed ID: 10182180
[TBL] [Abstract][Full Text] [Related]
18. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
19. Virus safety of prothrombin complex concentrates and factor IX concentrates.
Seitz R; Dodt J
Thromb Res; 1999 Aug; 95(4 Suppl 1):S19-23. PubMed ID: 10499905
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of viruses in blood and plasma products.
Suomela H
Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658
[No Abstract] [Full Text] [Related]
[Next] [New Search]